Chest pain without significant coronary stenosis after implantation of sirolimus-eluting stents

Internal Medicine

Volumn 48, Issue 4, 2009, Pages 213-217

  Hiasa, Ken Ichi ^a   Takemoto, Masao ^a   Matsukawa, Ryuichi ^a   Matoba, Tetsuya ^a   Kuga, Takeshi ^b   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b Mitsutake Hospital   (Japan)

Author keywords

Coronary intervention; Coronary vasoconstriction; Exercise; Microvessel dysfunction

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; AMLODIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; TICLOPIDINE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; HUMAN; ST SEGMENT DEPRESSION; THORAX PAIN; VASOSPASTIC ANGINA;

CHEST PAIN; DRUG-ELUTING STENTS; EXERCISE TOLERANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROVASCULAR ANGINA; MIDDLE AGED; SIROLIMUS;

EID: 61749097292     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1581     Document Type: Article

References (21)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (23): 1773-1780, 2002.
2. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (9562): 667-678, 2007.
3. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2): 231-236, 2005.
4. Maekawa K, Kawamoto K, Fuke S, et al. Images in cardiovascular medicine. Severe endothelial dysfunction after sirolimus-eluting stent implantation. Circulation 113 (23): e850-e851, 2006.
5. Muhlestein JB. Endothelial dysfunction associated with drug-eluting stents what, where, when, and how? J Am Coll Cardiol 51 (22): 2139-2140, 2008.
6. Ito A, Fukumoto Y, Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 44 (4): 480-485, 2004.
7. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 346 (25): 1948-1953, 2002.
8. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet 351 (9110): 1165-1169, 1998.
9. Mayer S, Hillis LD. Prinzmetal's variant angina. Clin Cardiol 21 (4): 243-246, 1998.
10. Hurst T, Olson TH, Olson LE, Appleton CP. Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment. Am J Med 119 (7): 560-566, 2006.
11. Okumura K, Osanai T, Kosugi T, et al. Enhanced phospholipase C activity in the cultured skin fibroblast obtained from patients with coronary spastic angina: possible role for enhanced vasoconstrictor response. J Am Coll Cardiol 36 (6): 1847-1852, 2000.
12. Cox ID, Kaski JC, Clague JR. Endothelial dysfunction in the absence of coronary atheroma causing Prinzmetal's angina. Heart 77 (6): 584, 1997.
13. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (1): 193-202, 2006.
14. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (10): 2108-2111, 2006.
15. Barilli A, Visigalli R, Sala R, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 78 (3): 563-571, 2008.
16. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 (6): 701-705, 2004.
17. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (1): 175-181, 2006.
18. Nakazawa G, Cheng Q, Xu X, Finn AV, Kolodgie FD, Virmani R. Drug-eluting stent implantation may not affect vasomotor function in early phase. J Am Coll Cardiol 51 (11): 1124-1125, 2008.
19. Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 51 (22): 2123-2129, 2008.
20. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (10): 1009-1019, 2007.
21. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (10): 1030-1039, 2007.